Division of Pediatric Respiratory Medicine, Rady Children's Hospital, University of California San Diego, San Diego, California, USA.
Division of Pulmonology and Critical Care, University of California San Diego, San Diego, California, USA.
Pediatr Pulmonol. 2024 Dec;59(12):3491-3498. doi: 10.1002/ppul.27236. Epub 2024 Aug 28.
Uncontrolled or severe asthma results in symptomatic usage of short-acting ß2-agonist (SABA) usage. MicroRNAs (miRNAs) are posttranslational regulators that can influence asthma biology. This study aims to identify miRNAs that are associated with increased SABA usage.
Small RNA sequenced from blood serum of 1,132 children with asthma aged 6 to 14 years in the Genetics of Asthma in Costa Rica Study was used for this analysis. Logistic regression identified miRNAs in patients who required increased SABA usage. These miRNA were validated for association with SABA-induced bronchodilator responsiveness (BDR). Gene target pathway analysis was performed on validated miRNAs.
Twenty-one miRNAs were significantly associated with increased SABA usage with OR ranging from 0.87 to 1.23. Two miRNAs, miR-378a-3p and miR-144-3p, had odds ratio 1.14 (1-1.29, p = .05) and 1.11 (1.01-1.22, p = .035), respectively, for increased SABA usage and were also significantly associated with bronchodilator response. Furthermore, a linear regression analysis involving these miRNA and bronchodilator response revealed that increased miR-378a-3p correlated with decreased BDR and increased expression of miR-144-3p correlated with improving pulmonary function with bronchodilators. In gene target Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, the erythroblastosis viral oncogene signaling pathway had among one of the highest fold enrichment and p-value.
Increased expression of miR-378a-3p and miR-144-3p was seen in this patient population who required increased SABA usage. There were different bronchodilatory effects seen in these two miRNAs, suggesting different potential mechanisms underlying increased SABA usage.
未控制或严重的哮喘会导致短效 β2-激动剂(SABA)的症状性使用。微小 RNA(miRNA)是一种翻译后调节因子,可以影响哮喘生物学。本研究旨在确定与 SABA 使用增加相关的 miRNA。
使用哥斯达黎加哮喘遗传学研究中 1132 名 6 至 14 岁哮喘儿童的血清小 RNA 测序进行本分析。逻辑回归确定了需要增加 SABA 使用的患者中的 miRNA。对这些 miRNA 进行了验证,以确定其与 SABA 诱导的支气管扩张剂反应性(BDR)的相关性。对验证的 miRNA 进行了基因靶标途径分析。
有 21 个 miRNA 与 SABA 使用增加显著相关,OR 范围为 0.87 至 1.23。miR-378a-3p 和 miR-144-3p 两个 miRNA 的比值比(OR)分别为 1.14(1-1.29,p=0.05)和 1.11(1.01-1.22,p=0.035),与 SABA 使用增加相关,与支气管扩张剂反应也显著相关。此外,涉及这些 miRNA 和支气管扩张剂反应的线性回归分析表明,miR-378a-3p 表达增加与 BDR 降低相关,miR-144-3p 表达增加与支气管扩张剂改善肺功能相关。在基因靶标京都基因与基因组百科全书(KEGG)途径分析中,红细胞生成病毒致癌基因信号通路具有最高的折叠富集和 p 值之一。
在需要增加 SABA 使用的患者人群中观察到 miR-378a-3p 和 miR-144-3p 的表达增加。这两种 miRNA 具有不同的支气管扩张作用,表明 SABA 使用增加的潜在机制不同。